Quality of life and survivorship in patients with low-grade ovarian cancer.

High-grade (HGOC) and low-grade ovarian carcinoma (LGOC) are distinct malignancies with different biological features, treatment paradigms, and life expectancies. However, differences in quality of life (QOL), sleep, and depressive symptoms have not been examined by grade, and neither have inflammatory profiles associated with these symptoms. We aim to characterize QOL and biomarkers by OC grade. Participants included patients with HGOC (N = 578) or LGOC (N = 85). Participants completed baseline assessments of psychosocial factors prior to primary surgery or neoadjuvant chemotherapy and contributed saliva for cortisol and blood for interleukin-6 (IL-6) quantification. Samples were collected intraoperatively to quantify tumor cortisol. General linear models were used to examine differences in biological and psychological variables by grade. At baseline, patients with LGOC reported less depression (p = 0.018) and sleep disturbances (p = 0.014), but no significant difference in depressive mood (p = 0.11) or QOL (p = 0.51) compared to patients with HGOC, adjusting for age and disease stage. There were trends towards lower tumor cortisol levels (p = 0.078) in LGOC compared to HGOC. One-year post-diagnosis, we found a significant improvement in QOL and fatigue, and a decrease in vegetative depression and IL-6 levels irrespective of grade. We present the first characterization of psychosocial experiences of patients with LGOC. Despite having a better disease prognosis, patients with LGOC were just as likely to have mood disturbances as those with HGOC. There was a trend towards differences in tumor cortisol by grade. Our findings highlight the need to address well-being in patients with both low- and high-grade ovarian malignancies.

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Dr. Thaker has done consulting for Iovance Biotherapeutics, Imunon, Merck, Eisai, Agenus, Immunogen, R-Pharm, Astra Zeneca, Clovis Oncology. Aadi Biosciences, Glaxo Smith Kline, Relacorilant, Seagen, Mersana, Novocure, and Verastem. Merck and Glaxo Smith Kline have provided institutional research grants. Immunon has provided shares to Dr. Thaker. Dr. Sood has done consulting for Merck, GSK, ImmunoGen, Astra Zeneca, Kiyatec, Iylon, Onxeo and is a shareholder for BioPath. Dr. Lutgendorf is a shareholder for AbbVie.